Month: November 2025

Matthew Crawford The rapid commercialization of glucagon-like peptide-1 (GLP-1) analogs has reshaped the therapeutic and manufacturing landscape, driving innovation across peptide development platforms. However, the path from early discovery to commercial-scale manufacturing presents significant challenges—particularly in translating flexible, high-throughput purification…